Journey Medical (NASDAQ:DERM) Downgraded by Wall Street Zen to Hold

Journey Medical (NASDAQ:DERM - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Sunday.

Several other equities research analysts also recently weighed in on DERM. Alliance Global Partners reiterated a "buy" rating on shares of Journey Medical in a report on Thursday, May 15th. Industrial Alliance Securities set a $10.50 price target on Journey Medical in a report on Thursday, March 27th.

Journey Medical Trading Up 0.9%

Shares of NASDAQ:DERM traded up $0.06 during trading on Friday, hitting $7.10. The company had a trading volume of 84,240 shares, compared to its average volume of 89,734. The stock has a market cap of $165.40 million, a price-to-earnings ratio of -18.21 and a beta of 0.80. Journey Medical has a one year low of $3.54 and a one year high of $8.25. The company has a fifty day simple moving average of $7.03 and a two-hundred day simple moving average of $5.83. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.34 and a quick ratio of 1.03.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.06. Journey Medical had a negative return on equity of 52.03% and a negative net margin of 14.76%. The business had revenue of $13.14 million during the quarter, compared to analyst estimates of $12.05 million. As a group, equities analysts forecast that Journey Medical will post -1.02 earnings per share for the current year.

Insider Buying and Selling

In other Journey Medical news, CEO Claude Maraoui sold 4,834 shares of the firm's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $6.84, for a total transaction of $33,064.56. Following the transaction, the chief executive officer directly owned 2,348,313 shares in the company, valued at $16,062,460.92. This trade represents a 0.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 15.03% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of DERM. Titleist Asset Management LLC increased its holdings in shares of Journey Medical by 18.3% in the 1st quarter. Titleist Asset Management LLC now owns 12,900 shares of the company's stock valued at $76,000 after acquiring an additional 2,000 shares during the period. Cetera Investment Advisers increased its holdings in shares of Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after acquiring an additional 2,478 shares during the period. Jane Street Group LLC purchased a new position in shares of Journey Medical in the 1st quarter valued at $110,000. Dimensional Fund Advisors LP purchased a new position in shares of Journey Medical in the 4th quarter valued at $80,000. Finally, Kovitz Investment Group Partners LLC increased its holdings in shares of Journey Medical by 112.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company's stock valued at $97,000 after acquiring an additional 13,105 shares during the period. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.